![Enliven Therapeutics Inc](/common/images/company/N_ELVN.png)
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.48 | 2.2641509434 | 21.2 | 22.91 | 20.67 | 257573 | 21.64363245 | CS |
4 | -0.04 | -0.184162062615 | 21.72 | 23.18 | 20.4 | 251958 | 21.7254837 | CS |
12 | -3.39 | -13.5221380136 | 25.07 | 25.96 | 20.16 | 221831 | 22.52985078 | CS |
26 | -2.08 | -8.75420875421 | 23.76 | 30.03 | 20.16 | 233242 | 24.45580398 | CS |
52 | 5.27 | 32.1145642901 | 16.41 | 30.03 | 10.9001 | 264910 | 22.79770004 | CS |
156 | -2.52 | -10.4132231405 | 24.2 | 30.03 | 9.8 | 208711 | 20.88177367 | CS |
260 | -2.52 | -10.4132231405 | 24.2 | 30.03 | 9.8 | 208711 | 20.88177367 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約